Bioxytran (BIXT) insider boosts preferred share holdings

Rhea-AI Filing Summary

Bioxytran, Inc. (BIXT) reported insider purchases by a company director. On 08/12/2025, the director acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same director acquired an additional 38,588 preferred shares at a price of $0.35 per share. Following these transactions, the director beneficially owned 379,177 preferred shares, held in direct ownership.

Insider Trade Summary

Net Buyer: 49,005 shares

Net Buy 2 txns

Insider CONAWAY DALE H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	preferred	38,588	$0.35	$14K
Grant/Award	preferred	10,417	$0.485	$5K

Holdings After Transaction: preferred — 379,177 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/18/2025 - 04:07 PM Learn about SEC filing dates

FAQ

What insider transaction did Bioxytran (BIXT) report in this Form 4?

A Bioxytran (BIXT) director reported purchasing preferred shares in two transactions, one on 08/12/2025 and another on 11/14/2025.

How many Bioxytran (BIXT) preferred shares were purchased and at what prices?

The director acquired 10,417 preferred shares at $0.485 per share on 08/12/2025 and 38,588 preferred shares at $0.35 per share on 11/14/2025.

What is the reporting person’s relationship to Bioxytran (BIXT)?

The reporting person is identified as a Director of Bioxytran, Inc.

How many Bioxytran (BIXT) preferred shares does the director own after these transactions?

After the reported transactions, the director beneficially owned 379,177 preferred shares.

Is the Bioxytran (BIXT) Form 4 filed by one person or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person.

What type of security is involved in the Bioxytran (BIXT) insider transactions?

The transactions involve preferred shares of Bioxytran, Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CONAWAY DALE H

(Last) (First) (Middle)

189 WELLS AVE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	08/12/2025		A		10,417	A	$0.485	340,589	D
preferred	11/14/2025		A		38,588	A	$0.35	379,177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Dale Conaway	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.